---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-017924"
form_type: "8-K"
ticker: "ASMB"
cik: "0001426800"
company_name: "ASSEMBLY BIOSCIENCES, INC."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T21:33:24.454447+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Assembly Biosciences Q1 net loss $19M; cash $73M; herpesvirus candidate ABI-5366 advancing to IND

## Summary
- Net loss of $19.0M ($0.37 per share) vs $23.1M ($0.48) in Q1 2022; R&D expenses $14.5M down from $17.2M.
- Cash, cash equivalents and marketable securities $73.0M as of March 31, 2023, projected to fund ops into Q3 2024.
- Nominated first herpesvirus candidate ABI-5366; plans to enter clinic first half 2024; expects additional candidate nomination in 2023.
- Evaluating partnering options for core HBV inhibitor portfolio to focus on expanded virology programs.
- Multiple abstracts accepted for presentation at EASL 2023 in June for HBV/HDV entry inhibitor and core inhibitor data.

## SEC filing metadata
- accession: 0000950170-23-017924
- form_type: 8-K
- ticker: ASMB
- cik: 0001426800
- company_name: ASSEMBLY BIOSCIENCES, INC.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1426800/000095017023017924/0000950170-23-017924-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1426800/000095017023017924/asmb-20230504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-017924
- JSON: https://secwatch.observer/filing/0000950170-23-017924.json
- Plain text: https://secwatch.observer/filing/0000950170-23-017924.txt

## Key facts
- Earnings Releases
  ASSEMBLY BIOSCIENCES, INC. reported first quarter ended March 31, 2023 results: net income $19.0 million, EPS $0.37 per basic and diluted share.
  - Period: first quarter ended March 31, 2023
  - Net income: $19.0 million
  - EPS: $0.37 per basic and diluted share
  - Result: reported results
  source text: Net loss attributable to common stockholders was $19.0 million, or $0.37 per basic and diluted share, for the three months ended March 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1426800/000095017023017924/0000950170-23-017924-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.